NSF: Still relevant

Journal of Magnetic Resonance Imaging

Volumn 40, Issue 1, 2014, Pages 11-12

  Thomsen, Henrik S ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; GADODIAMIDE; GADOLINIUM; GADOLINIUM PENTETATE MEGLUMINE; GADOVERTISAMIDE; UNCLASSIFIED DRUG;

CONTRAST ENHANCEMENT; CONTRAST INDUCED NEPHROPATHY; DENMARK; DISEASE SEVERITY; DRUG CONTRAINDICATION; EDITORIAL; EUROPE; FOOD AND DRUG ADMINISTRATION; GLOMERULUS FILTRATION RATE; HUMAN; INCIDENCE; KIDNEY FUNCTION; NEPHROGENIC SYSTEMIC FIBROSIS; NEPHROLOGIST; NORTH AMERICA; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PREGNANT WOMAN; PRIORITY JOURNAL; RADIOLOGIST; CHEMICALLY INDUCED; DIAGNOSTIC USE; DOSE RESPONSE; NEPHROGENIC FIBROSING DERMOPATHY; PATIENT SAFETY;

CONTRAST MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING; NEPHROGENIC FIBROSING DERMOPATHY; PATIENT SAFETY;

EID: 84902388394     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.24422     Document Type: Editorial

References (19)

1. Thomsen HS, Morcos SK, Almén T, et al. Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Media Safety Committee guidelines. Eur Radiol 2013; 23: 307-318.
2. Thomsen HS,. Nephrogenic systemic fibrosis and gadolinium-based contrast media (Chapter 26). In:, Thomsen HS, Webb JAW, editors. Contrast media: safety issues and ESUR guidelines. Heidelberg: Springer; 2013 (in press).
3. Broome DR,. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. Eur J Radiol 2008; 6: 230-234.
4. Pirovano G, Munley J, Schultz C, et al. Nephrogenic systemic fibrosis: a review of published cases and results from three prospective observational studies. ECR 2012 Book of Abstracts. Insights Imaging 2012; 3 (Suppl 1): S293.
5. Marckmann P, Skov L, Rossen K, Thomsen HS,. Clinical manifestation of gadodiamide-related nephrogenic systemic fibrosis. Clin Nephrol 2008; 69: 161-168.
6. Wertman R, Altun E, Martin DR,. Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities. Radiology 2008; 248: 799-806.
7. Rydahl C, Thomsen HS, Marckman P,. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium(Gd)-containing magnetic resonance contrast agent. Invest Radiol 2008; 43: 141-144.
8. Tsushima Y, Kanal E, Thomsen HS,. Nephrogenic systemic fibrosis: risk factors suggested from Japanese published cases. Brit J Radiol 2010; 83: 590-595.
9. Bennett CL, Qureshi ZP, Sator OA, et al. Gadolinium induced nephrogenic systemic fibrosis, the rise and fall of an iatrogenic disease. Clin Kidney J 2012; 5: 82-88.
10. Chang HJ,. Researchers focus on contrast safety. JAMA 2010; 303: 1244.
11. Commission Decision of 1.7.2010 concerning, in the framework of Article 31 of Directive 2001/83/EC of the European Parliament and of the Council, the marketing authorisations for gadolinium-containing contrast agents for human use which contain one or more of the active substances "gadodiamide, gadopentetic acid, gadobenic acid, gadoxetic acid, gadoteridol, gadobutrol and gadoteric acid." Available at: http://ec.europa.eu/health/documents/ community-register/html/refh-others.htm. Accessed August 2013.
12. Amet S, Choukroun G, Launay-Vacher V, et al. Prevalence of nephrogenic systemtic fibrosis in dialysis patients: the Pro-FINEST study. ECR 2012 Book of Abstracts Insights Imaging 2012; 3:(Suppl 1): S293.
13. Thomsen HS,. Contrast medium-induced nephropathy (Chapter 12). In:, Thomsen HS, Webb JAW, editors. Contrast media: safety issues and ESUR guidelines. Heidelberg: Springer; 2013 (in press).
14. Grant D, Johnsen A, Juelsrud A, Løvhaug D,. Effects of gadolinium contrast agents in naíve and nephrectomized rats: relevance to nephrogenic systemic fibrosis. Acta Radiol 2009; 50: 156-169.
15. Evans CH, Drouven BJ,. The promotion of collagen polymerization by lanthanide and calcium ions. Biochem J 1983; 213: 751-758.
16. Evans CH,. Biochemistry of the lanthanides. New York: Plenum Press; 1990.
17. SMRM workshop on contrast enhanced magnetic resonance. Discussion. Magn Reson Med 1991; 22: 229-232.
18. Tweedle MF, Gaughan GT, Hagan J, et al. Considerations involving paramagnetic coordination compounds as useful NMR contrast agents. Nucl Med Biol Int J Radiat Appl Instrum Part B 1988: 15: 31-36.
19. Telgmann L, Sperling M, Karsta U,. Determination of gadolinium-based MRI contrast agents in biological and environmental samples: a review. Anal Chim Acta 2013; 764: 1-16.